ERBB2 and breast cancer: The most recent guidelines from national organizations [8–10] emphasize the importance of a complete pathology assessment of invasive BC (i.e., tumor size, grade, endocrine receptor status, and HER2 amplification) prior to genomic test selection and therapeutic sequencing, including surgery.